EP3624839A4 - Anti-cd33 immunoconjugate dosing regimens - Google Patents
Anti-cd33 immunoconjugate dosing regimens Download PDFInfo
- Publication number
- EP3624839A4 EP3624839A4 EP18802489.7A EP18802489A EP3624839A4 EP 3624839 A4 EP3624839 A4 EP 3624839A4 EP 18802489 A EP18802489 A EP 18802489A EP 3624839 A4 EP3624839 A4 EP 3624839A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- dosing regimens
- immunoconjugate
- immunoconjugate dosing
- regimens
- dosing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940127121 immunoconjugate Drugs 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762507636P | 2017-05-17 | 2017-05-17 | |
US201762523112P | 2017-06-21 | 2017-06-21 | |
US201762579779P | 2017-10-31 | 2017-10-31 | |
US201762596377P | 2017-12-08 | 2017-12-08 | |
US201862660096P | 2018-04-19 | 2018-04-19 | |
PCT/US2018/032945 WO2018213430A1 (en) | 2017-05-17 | 2018-05-16 | Anti-cd33 immunoconjugate dosing regimens |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3624839A1 EP3624839A1 (en) | 2020-03-25 |
EP3624839A4 true EP3624839A4 (en) | 2021-06-16 |
Family
ID=64274787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18802489.7A Withdrawn EP3624839A4 (en) | 2017-05-17 | 2018-05-16 | Anti-cd33 immunoconjugate dosing regimens |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3624839A4 (en) |
JP (1) | JP2020519640A (en) |
MA (1) | MA49152A (en) |
WO (1) | WO2018213430A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200276339A1 (en) * | 2017-12-04 | 2020-09-03 | Actinium Pharmaceuticals, Inc. | Methods for treatment of patients with myelodysplastic syndromes |
JP7474195B2 (en) | 2018-01-12 | 2024-04-24 | イミュノジェン, インコーポレイテッド | Methods for antibody drug conjugation, purification, and formulation |
TW202003048A (en) | 2018-05-15 | 2020-01-16 | 美商伊繆諾金公司 | Combination treatment with antibody-drug conjugates and FLT3 inhibitors |
JP2021526525A (en) * | 2018-06-07 | 2021-10-07 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | Treatment method using antibody drug conjugate (ADCS) |
JP2022538117A (en) * | 2019-06-26 | 2022-08-31 | メモリアル スローン ケタリング キャンサー センター | Anti-CD33 antibodies for treating cancer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004043344A2 (en) * | 2002-11-07 | 2004-05-27 | Immunogen, Inc. | Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
WO2015179400A2 (en) * | 2014-05-20 | 2015-11-26 | Immunogen,Inc. | Methods for characterizing and treating acute myeloid leukemia |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130309223A1 (en) * | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
-
2018
- 2018-05-16 EP EP18802489.7A patent/EP3624839A4/en not_active Withdrawn
- 2018-05-16 WO PCT/US2018/032945 patent/WO2018213430A1/en unknown
- 2018-05-16 MA MA049152A patent/MA49152A/en unknown
- 2018-05-16 JP JP2019562396A patent/JP2020519640A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004043344A2 (en) * | 2002-11-07 | 2004-05-27 | Immunogen, Inc. | Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
WO2015179400A2 (en) * | 2014-05-20 | 2015-11-26 | Immunogen,Inc. | Methods for characterizing and treating acute myeloid leukemia |
Non-Patent Citations (1)
Title |
---|
See also references of WO2018213430A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2020519640A (en) | 2020-07-02 |
MA49152A (en) | 2020-03-25 |
WO2018213430A1 (en) | 2018-11-22 |
EP3624839A1 (en) | 2020-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI800506B (en) | Immunoconjugates | |
EP3615076A4 (en) | Anti-cd33 antibody agents | |
EP3322735A4 (en) | Drug-conjugated bi-specific antigen-binding constructs | |
EP3417133C0 (en) | Hinge | |
EP2997044A4 (en) | Anti-folr1 immunoconjugate dosing regimens | |
EP3624839A4 (en) | Anti-cd33 immunoconjugate dosing regimens | |
EP3055332A4 (en) | Anti-folr1 immunoconjugate dosing regimens | |
PT3347054T (en) | Dosing regimens for anti-tf-antibody drug-conjugates | |
IL279005A (en) | Anti-cd37 immunoconjugate dosing regimens | |
HK1259491A1 (en) | Dosing regimens | |
EP3606465A4 (en) | Dosing regimens and related compositions and methods | |
PL3325365T3 (en) | Package with two-part hinge | |
EP3724211A4 (en) | Dosing regimens and related compositions and methods | |
IL267893B (en) | Thiobenzoimidazole as fungicides | |
EP3444945A4 (en) | Oscillator | |
IL280515A (en) | Dosing regimens for elagolix | |
GB2555670B (en) | Dosing assembly | |
IL271290A (en) | Dihydro-pyrrolo-pyridine derivatives | |
PL3296491T3 (en) | Adjustable latching hinge | |
PL3489450T3 (en) | Gate | |
EP3703728A4 (en) | Dosing regimens for celiac disease | |
GB2550987B (en) | Wrapping | |
GB201601469D0 (en) | Wrapper | |
GB201600015D0 (en) | Hinge | |
PL3695082T3 (en) | Gate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191217 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210519 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/00 20060101AFI20210512BHEP Ipc: C12Q 1/68 20180101ALI20210512BHEP Ipc: A61K 31/5517 20060101ALI20210512BHEP Ipc: G01N 33/574 20060101ALI20210512BHEP Ipc: A61P 35/00 20060101ALI20210512BHEP Ipc: A61P 35/02 20060101ALI20210512BHEP Ipc: C07K 16/28 20060101ALI20210512BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20211201 |